Kymera Therapeutics (KYMR) News Today $20.77 +0.01 (+0.05%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$19.73▼$20.9750-Day Range$10.97▼$20.8952-Week Range$9.60▼$39.85Volume364,797 shsAverage Volume736,775 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$39.30 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - November 25 at 3:32 AMAnalyst Expectations for Kymera Therapeutics's Futuremarkets.businessinsider.com - November 13 at 2:38 PMKymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicinefinance.yahoo.com - November 13 at 2:38 PMKymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseasesseekingalpha.com - November 12 at 2:27 AMBIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Incfinance.yahoo.com - November 7 at 1:25 PMKymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 5 at 5:53 PMKymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Resultses-us.finanzas.yahoo.com - November 4 at 10:13 PMHC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - November 3 at 3:57 PMAnalysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Kymera Therapeutics (KYMR)markets.businessinsider.com - November 3 at 9:48 AMKymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - November 2 at 8:35 AMKymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - November 2 at 8:35 AMPreview: Kymera Therapeutics's Earningsbenzinga.com - November 1 at 2:47 PMKymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofifinance.yahoo.com - October 27 at 7:45 AMWill Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Knowfinance.yahoo.com - October 26 at 3:19 PMKymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2finance.yahoo.com - October 26 at 10:18 AMKymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerfinance.yahoo.com - October 19 at 3:21 PMKymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerfinance.yahoo.com - October 18 at 1:25 PMKymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinomafinance.yahoo.com - October 16 at 8:18 AMKymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?finance.yahoo.com - October 4 at 8:46 AMWhy Shares of Kymera Therapeutics Jumped on Tuesdayfinance.yahoo.com - October 3 at 8:44 PMHarbor Capital Advisors Inc. Buys 20,059 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)marketbeat.com - September 19 at 6:38 AMKymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphomafinance.yahoo.com - September 18 at 9:22 AMKymera Therapeutics, Inc. (NASDAQ:KYMR) is Atlas Venture Life Science Advisors LLC's Largest Positionmarketbeat.com - September 12 at 6:13 AMProfund Advisors LLC Makes New $1.15 Million Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)marketbeat.com - September 1 at 7:53 AMIndustry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19%finance.yahoo.com - August 31 at 7:29 AMMorgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendationmsn.com - August 30 at 9:23 AMThe Latest Analyst Ratings for Kymera Therapeuticsmarkets.businessinsider.com - August 29 at 6:23 PMKymera Therapeutics to Participate in Upcoming September Investor Conferencesfinance.yahoo.com - August 28 at 10:10 AMKymera Therapeutics - Need More Developments Before Making This A Buymsn.com - August 9 at 5:40 PMSG Americas Securities LLC Invests $260,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)marketbeat.com - August 9 at 4:35 AMStifel Maintains Kymera Therapeutics (KYMR) Buy Recommendationmsn.com - August 8 at 1:21 PMKymera Therapeutics, Inc. (NASDAQ:KYMR) Position Trimmed by Barclays PLCmarketbeat.com - August 8 at 6:11 AMTruist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)markets.businessinsider.com - August 7 at 2:55 AMKymera Therapeutics: A Status Updateseekingalpha.com - August 6 at 7:21 AMKymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Resultsmarketbeat.com - August 4 at 8:24 PMH.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)markets.businessinsider.com - August 4 at 5:50 PMHC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendationmsn.com - August 4 at 5:50 PMExpert Ratings for Kymera Therapeuticsmarkets.businessinsider.com - August 4 at 5:50 PMCredit Suisse Group Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $37.00marketbeat.com - August 4 at 11:26 AMKymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - August 3 at 8:37 AMKymera Therapeutics (KYMR) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - July 28 at 10:17 AMKymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3finance.yahoo.com - July 27 at 10:56 AMRaymond James & Associates Has $679,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)marketbeat.com - July 25 at 4:20 AMKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - July 23 at 4:36 AMCompanies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growthfinance.yahoo.com - July 9 at 10:20 AMTruist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendationmsn.com - July 1 at 12:21 PMKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from Analystsmarketbeat.com - June 28 at 4:30 AMFDA grants orphan drug status to Kymera blood cancer drug KT-253seekingalpha.com - June 22 at 2:16 PMKymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemiafinance.yahoo.com - June 22 at 9:16 AMBoard Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Sharesbenzinga.com - June 21 at 1:20 PM Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼1.230.76▲Average Medical News Sentiment KYMR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼12▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BCRX News Today RLAY News Today INBX News Today VIR News Today SWTX News Today EDIT News Today APGE News Today RGNX News Today ADMA News Today SRRK News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:KYMR) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.